华夏恒生生物科技ETF(QDII)(159892)利润分配表
|
2025-06-30 |
2024-12-31 |
2024-06-30 |
2023-12-31 |
收入 |
1,805,736,777.71 |
-262,972,621.44 |
-769,534,744.28 |
-226,860,490.31 |
利息合计 |
156,051.71 |
614,860.52 |
260,054.39 |
603,877.08 |
其中:存款利息收入 |
156,051.71 |
614,860.52 |
260,054.39 |
603,877.08 |
债券利息收入 |
- |
- |
- |
- |
资产支持证券利息收入 |
- |
- |
- |
- |
买入返售金融资产收入 |
- |
- |
- |
- |
投资收益合计 |
398,223,473.56 |
-126,545,902.32 |
-110,316,436.68 |
-47,433,939.01 |
其中:股票投资收益 |
381,208,869.90 |
-165,014,737.64 |
-129,488,943.45 |
-59,123,459.21 |
基金投资收益 |
-9,332.91 |
- |
- |
- |
债券投资收益 |
- |
- |
- |
- |
资产支持证券投资收益 |
- |
- |
- |
- |
衍生工具收益 |
- |
-175,908.27 |
-175,908.27 |
-352,221.53 |
股利收益 |
17,023,936.57 |
38,644,743.59 |
19,348,415.04 |
12,041,741.73 |
基金分红收益收益 |
- |
- |
- |
- |
公允价值变动收益 |
1,419,776,831.25 |
-171,129,385.05 |
-678,850,201.69 |
-217,722,710.04 |
其他收入 |
-12,440,498.63 |
32,690,698.18 |
18,218,618.01 |
37,870,500.02 |
费用 |
14,053,841.98 |
20,211,266.72 |
8,528,742.00 |
9,698,649.23 |
管理人报酬 |
10,606,246.53 |
15,225,654.76 |
6,412,771.18 |
7,236,938.32 |
基金托管费 |
3,192,232.02 |
4,567,696.41 |
1,923,831.31 |
2,171,081.49 |
销售服务费 |
- |
- |
- |
- |
交易费用 |
- |
- |
- |
- |
利息支出 |
- |
- |
- |
- |
其中:卖出回购金融资产支出 |
- |
- |
- |
- |
其他费用 |
255,363.43 |
417,915.55 |
192,139.51 |
290,629.42 |
利润总额 |
1,791,682,935.73 |
-283,183,888.16 |
-778,063,486.28 |
-236,559,139.54 |